L
Lina He
Researcher at Stanford University
Publications - 18
Citations - 3851
Lina He is an academic researcher from Stanford University. The author has contributed to research in topics: In vivo & Biodistribution. The author has an hindex of 16, co-authored 18 publications receiving 3689 citations.
Papers
More filters
Journal ArticleDOI
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice
Zhuang Liu,Weibo Cai,Lina He,Nozomi Nakayama,Kai Chen,Xiaoming Sun,Xiaoyuan Chen,Hongjie Dai +7 more
TL;DR: It is found that SWNTs that are functionalized with phospholipids bearing polyethylene-glycol (PEG) are surprisingly stable in vivo, and a high tumour accumulation is attributed to the multivalent effect of theSWNTs.
Journal ArticleDOI
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy
TL;DR: Functionalization of SWNTs by branched polyethylene-glycol (PEG) chains was developed, enabling thus far the longest SWNT blood circulation up to 1 day, relatively low uptake in the reticuloendothelial system (RES), and near-complete clearance from the main organs in ≈2 months.
Journal ArticleDOI
64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression
TL;DR: Polyvalency has a profound effect on the receptor-binding affinity and in vivo kinetics of radiolabeled RGD multimers, as compared with the other RGD analogs.
Journal ArticleDOI
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody
TL;DR: The success of EGFR-positive tumor imaging using 64Cu-DOTA-cetuximab can be translated into the clinic to characterize the pharmacokinetics, to select the right population of patients for EGFR -targeted therapy, and to monitor the therapeutic efficacy of anti-EGFR treatment.
Journal ArticleDOI
microPET of Tumor Integrin αvβ3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4)
TL;DR: The tetrameric RGD peptide tracer 18F-FPRGD4 possessing high integrin-binding affinity and favorable biokinetics is a promising tracer for PET of integrin αvβ3 expression in cancer and other angiogenesis related diseases.